iSTAR Medical Basic Information, Manufacturing Base, Sales Area, and Competitors
|
Sr. No. |
Item |
Description |
|
1 |
Company Name |
iSTAR Medical |
|
2 |
Website |
www.istar-medical.com |
|
3 |
Established Date |
2011 |
|
4 |
Headquartered |
Belgium |
|
5 |
Market Position/ History |
iSTAR Medical is a clinical-stage medtech company headquartered in Wavre, Belgium, founded in 2011. The company specializes in developing minimally invasive ophthalmic implants, particularly for the treatment of glaucoma, which is the leading cause of irreversible blindness globally. |
|
6 |
Sales Area |
Europe and Asia Pacific |
|
7 |
Manufacturing Location |
Belgium |
|
8 |
Competitors |
|
|
9 |
CEO |
Michel Vanbrabant |
|
10 |
Ownership Type |
Private |
|
11 |
Contact Information |
Avenue Sabin, 6, 1300 Wavre, Belgium Tel: +32 10 77 16 54 |
Business Segment/ Overview:
iSTAR Medical specializes in developing minimally invasive ophthalmic implants, particularly for the treatment of glaucoma, which is the leading cause of irreversible blindness globally.
The flagship product of ISTAR Medical is MINIject, a microinvasive glaucoma surgery (MIGS) device designed to effectively reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma. This innovative device is made from a proprietary material known as STAR, which is notable for its anti-fibrotic and anti-inflammatory properties. MINIject facilitates the outflow of aqueous humor from the anterior chamber to the supraciliary space, resulting in significant IOP reduction—clinical trials indicate a mean reduction of over 40% at two years post-surgery.
Micro Invasive Glaucoma Surgery MIGS Device Product Types Specification
|
Product |
Description |
|
Minijet S |
MINIject S is iSTAR Medical’s revolutionary, supraciliary MIGS device. The uveoscleral drainage pathway is known to lower IOP significantly; The negative pressure gradient from the anterior chamber to the supraciliary space evacuates aqueous humor, unhindered by an episcleral venous pressure floor. MINIjectS now allows ophthalmic surgeons to harness this potential in a safe and predictable way. MINIject S combines a smart way to access the supraciliary space with a uniquely designed, soft and flexible implant which has proven its long-term safety and sustained efficacy in lowering IOP. MINIject is only available for sale in the European Union, the UK, Norway, Iceland, Switzerland and Australia. Key Features of MINIject:
|
Recent Developments:
|
Year |
Latest News |
|
July 2022 |
AbbVie and iSTAR Medical Announced Strategic Alliance for the Treatment of Glaucoma AbbVie and iSTAR Medical SA, announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance will support iSTAR Medical's development and commercial efforts for MINIject, as well as provide an opportunity to expand AbbVie's eye care business, building on its glaucoma portfolio which includes drops, sustained release implants, and stent offerings. |
Author's Detail:
Vinayak Bali /
LinkedIn
Catering to tailored needs of clients in Consulting, Business Intelligence, Market Research, Forecasting, Matrix-Modelling, Data Analytics, Competitive Intelligence, Primary research and Consumer Insights. Experience in analyzing current trends, market demand, market assessment, growth indicators, competitors' strategy, etc. to help top management & investors to make strategic and tactical decisions in the form of market reports and presentations. Successfully delivered more than 500+ client & consulting assignments across verticals. Ability to work independently as well as with a team with confidence and ease.
I am committed to continuous learning and staying at the forefront of emerging trends in research and analytics. Regularly engaging in professional development opportunities, including workshops and conferences, keeps my skill set sharp and up-to-date. I spearheaded research initiatives focused on market trends and competitive landscapes. I have a proven track record of conducting thorough analyses, distilling key insights, and presenting findings in a way that resonates with diverse stakeholders. Through collaboration with cross-functional teams, I played a pivotal role in shaping business strategies rooted in robust research.